Navigation Links
YM BioSciences presents CYT387 and CYT997 data at international cancer conference
Date:2/11/2010

events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BioSciences granted two US patents for AeroLEF(R)
2. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
3. YM BioSciences reports second quarter 2010 operational and financial results
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
7. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
8. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
9. YM BioSciences announces result of Cytopia shareholder vote
10. Profectus Biosciences to Present at Key Investor Conference in January 2010
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... an electronic which is not only based on ... spin and the spin-related magnetism. Spin-charge converters enable ... vice versa. Recently, the research group of Professor ... Johannes Gutenberg University Mainz in collaboration with researchers ... the first time realised a new, efficient spin-charge ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... -- Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, today announced ... Itin, will participate in a panel discussion titled "Antibody ... Healthcare Conference on December 10, 2008. The Conference ...
... NEW BRUNSWICK, N.J., Dec. 5 Senesco Technologies, Inc. ... today that its Development and License Agreement with the ... mutual agreement because of Harris Moran,s recently announced corporate ... Harris Moran has reported that its parent company, Limagrain, ...
... China Sky One Medical,Inc. ("China Sky One Medical" or ... integrated pharmaceutical company producing over-the-counter drugs in,the People,s Republic ... CEO and President of China Sky One Medical took ... China Perspective. , ...
Cached Biology Technology:Micromet to Present at the RBC Capital Markets Healthcare Conference 2Micromet to Present at the RBC Capital Markets Healthcare Conference 3Micromet to Present at the RBC Capital Markets Healthcare Conference 4Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3China Sky One Medical, Inc. Interviewed in The China Perspective 2China Sky One Medical, Inc. Interviewed in The China Perspective 3
(Date:8/28/2014)... are good examples of complex systems. Their infrastructure ... water for cooling, transport to supply fuel, and ... in the network chain is interconnected with a ... A team of UK-based scientists has studied various ... findings have been published in EPJ B by ...
(Date:8/28/2014)... news release is available in German . ... products are now built with the help of sophisticated assembly ... fixed, are an important part of these assembly lines. In ... attached in various work stages arranged in a precise spatial ... end of the line. , The creation of such an ...
(Date:8/28/2014)... action is needed to ensure safeguards are in place ... PLOS ONE , researchers from Monash University, Stellenbosch ... combining results from different studies - to look at ... to determine whether they actually protect biodiversity. , ... an area from human exploitation made common sense, however, ...
Breaking Biology News(10 mins):Inter-dependent networks stress test 2Nanoscale assembly line 2Nanoscale assembly line 3Protected areas proven to protect biodiversity 2
... now one of the major reasons why couples travel ... circumvent regulations at home or raise concerns about financial ... controversial. Yet little is known about the women who ... characteristics, their motivation and their compensation. A study ...
... Studies over the past 20 years have suggested (though ... most evidently in falling sperm counts and,reduced sperm motility.(1) ... as exposure to toxins) and to male smoking. Now, ... of the world,s largest study cohorts, suggests that,exposure to ...
... 8 July 2013: The first birth has been achieved ... technique which promises to revolutionise embryo selection for IVF.,The ... screening of embryos, is reported,today at the annual meeting ... Biomedical Research,Centre at the University of Oxford, UK., The ...
Cached Biology News:Egg donation in European clinics: Why do women do it? 2Egg donation in European clinics: Why do women do it? 3Early life and in utero factors found to influence testicular function in adulthood 2Early life and in utero factors found to influence testicular function in adulthood 3First child born following embryo screening with new genome analysis technique 2First child born following embryo screening with new genome analysis technique 3
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Spastin (Sp 3G11/1)...
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
...
Biology Products: